Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Dec;37(12):2747-2753.
doi: 10.1007/s00345-019-02728-4. Epub 2019 Mar 23.

Patients choose certainty over burden in bladder cancer surveillance

Frits H M van Osch  1   2 , Duncan Nekeman  3 , Neil K Aaronson  4 , Lucinda J Billingham  5 , Nicholas D James  6 , K K Cheng  3 , Richard T Bryan  6 , Maurice P Zeegers  7
Affiliations
Comparative Study

Patients choose certainty over burden in bladder cancer surveillance

Frits H M van Osch et al. World J Urol. 2019 Dec.

Abstract

Background: Due to the high risk of recurrence of non-muscle invasive bladder cancer, all patients undergo regular cystoscopic surveillance for early detection. As cystoscopy is invasive, costly and increases the burden of the disease considerably, there is significant ongoing research and development into non-invasive urinary biomarker substitutes. This study aims to assess the level of sensitivity required before patients accept a new urinary biomarker.

Methods: We studied the preferences for a hypothetical diagnostic urinary biomarker and compared this to usual care (cystoscopy) at different levels of sensitivity among 437 patients with bladder cancer (354 men and 83 women) from the UK Bladder Cancer Prognosis Programme. A standard gamble approach was used to estimate the minimally acceptable sensitivity (MAS) of the new biomarker. Additionally, non-parametric statistical analyses were performed to investigate the association between surveillance preference and various patient characteristics.

Results: Almost half of patients (183, 43%) would not replace cystoscopy with a urinary biomarker unless it was 100% sensitive. The median MAS was 99.9999%, and nearly 85% of patients demanded a sensitivity of at least 99% before preferring a urinary biomarker test over cystoscopy. These results were consistent across all patient characteristics and demographic categories.

Conclusions: Our results indicate that patients demand urinary biomarkers as sensitive as cystoscopy before they would be willing to forego cystoscopy for bladder cancer surveillance.

Keywords: Non-invasive biomarkers; Non-muscle-invasive bladder cancer; Sensitivity and specificity; Standard gamble.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest. All participants in this study provided written informed consent.

Figures

Fig. 1
Fig. 1
Flow chart depicting patient recruitment in the Bladder Cancer Prognosis Programme (BCPP) cohort study and inclusion for the current study
See this image and copyright information in PMC

References

    1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU Int. 2013;112(2):169–175. doi: 10.1111/bju.12032. - DOI - PubMed
    1. Boustead GB, Fowler S, Swamy R, Kocklebergh R, Hounsome L. Section of oncology, BAUS. Stage, grade and pathological characteristics of bladder cancer in the UK: British association of urological surgeons (BAUS) Urol Tumour Registry. BJU Int. 2014;113(6):924–930. doi: 10.1111/bju.12468. - DOI - PubMed
    1. van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442. doi: 10.1016/j.eururo.2009.06.028. - DOI - PubMed
    1. Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ. ICUD-SIU international consultation on bladder cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019;37:51–60. doi: 10.1007/s00345-018-2438-9. - DOI - PubMed

Publication types

Substances